Delivery Order SPE2DB22D3009-SPE2DB25FBF89
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 23, 2025, for the supply of Envarsus XR 1 mg tablets in a quantity of 100s, with a ceiling value of $1,718.48 and a firm fixed price structure. This is a non-set-aside, competitively awarded contract that will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania, with an ultimate completion date of October 15, 2025. The delivery order is issued under...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 28, 2025, for the supply of Envarsus XR 1 mg tablets in quantities of 100 units. This competitively awarded, firm fixed-price delivery order carries a ceiling value of $1,718.48 and is scheduled for completion by September 19, 2025. The order will be fulfilled from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. As a child contract action under a larger vehicle, this...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 17, 2025, for the supply of Envarsus XR 4 mg tablets (100-count packages) with a ceiling value of $1,711.95. This firm fixed-price delivery order is scheduled for completion by October 8, 2025, and will be fulfilled from the vendor's facility in Conshohocken, Pennsylvania. The contract carries no set-aside designation, indicating it was competitively awarded through open procurement processes....
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 19, 2025, for the supply of Envarsus XR 4 mg tablets (100-count units) with a contract ceiling value of $5,135.85. This is a firm fixed-price delivery order with an ultimate completion date of September 10, 2025, and represents no set-aside contract, indicating it was competitively awarded. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 24, 2025, for the supply of Envarsus XR 4 mg tablets (100-count packages) with a contract ceiling value of $1,711.95. This firm fixed-price delivery order, which has an ultimate completion date of October 16, 2025, represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical. The award was made through open competition with no set-aside...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 29, 2025, for the supply of Envarsus XR 1 mg tablets (100-count) with a ceiling value of $1,288.86. This non-set-aside, competitively awarded contract is structured as a firm fixed price delivery order with an ultimate completion date of September 22, 2025. The pharmaceutical product will be delivered to the company's corporate office location in Conshohocken, Pennsylvania. This delivery order is...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 15, 2025, for the supply of Envarsus XR 4 mg tablets (100 count) with a contract value of $6,847.80. This competitively awarded, non-set-aside delivery order is classified as firm fixed price and will be completed by October 6, 2025, with performance at the contractor's facility in Conshohocken, Pennsylvania. The award represents a child contract under AmerisourceBergen Drug Corp's substantial...
- The Defense Logistics Agency's Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on September 22, 2025, for the supply of Envarsus XR 1 mg tablets (30-count units) with a ceiling value of $2,723.16. The contract is structured as a firm fixed-price delivery order with a completion date of October 14, 2025, and represents a non-competed award. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor and critical...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 8, 2025, for the supply of Envarsus XR 4 mg tablets (100-count units) with a ceiling value of $1,711.95 and a firm fixed-price structure. This non-set-aside, competitively awarded delivery order is scheduled for completion by September 29, 2025, and will be performed at the contractor's facility in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 20, 2025, for the supply of Envarsus XR 1 mg tablets in a quantity of 100 units. This competitively awarded, non-set-aside contract carries a ceiling value of $1,718.48 with firm fixed pricing and is scheduled for completion by September 11, 2025. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a child contract...
- SPE2DB22D3009Indefinite Delivery Contract
- SPE2DB22D3009-SPE2DB25FBF89Delivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 27, 2025, for the supply of Envarsus XR 4 mg tablets (100-count packages) under a firm fixed-price contract valued at $5,135.85, with completion scheduled for October 20, 2025. The contract was competitively awarded without a set-aside designation and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026, which serves as a comprehensive global pharmaceutical support vehicle for military healthcare programs worldwide. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, maintains a significant role in the federal medical supply chain, particularly supporting Defense Health Agency and military healthcare systems. The company's extensive contract portfolio with the DLA encompasses a wide range of pharmaceutical products, including specialty medications, brand-name and generic drugs, vaccines, and medical supplies across multiple therapeutic domains. This specific order for Envarsus XR—a transplant immunosuppressant medication—reflects the contractor's demonstrated capability to fulfill federal medical procurement requirements through open competition and represents a routine transaction within the broader pharmaceutical prime vendor relationship.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $5.1k | 9/27/25 |